CHDSA
MCID: CHN012
MIFTS: 57

Chondrosarcoma (CHDSA)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Chondrosarcoma

MalaCards integrated aliases for Chondrosarcoma:

Name: Chondrosarcoma 58 12 77 54 60 76 30 13 56 6 45 15 41 17 74
Cartilaginous Cancer 12 54
Primary Chondrosarcoma of the Bone 12
Chondrosarcoma of Bone 12
Chdsa 76

Characteristics:

Orphanet epidemiological data:

60
chondrosarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
chondrosarcoma:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 60  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3371
OMIM 58 215300
MeSH 45 D002813
NCIt 51 C2946 C7155
SNOMED-CT 69 14990007
MESH via Orphanet 46 D002813
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0008479
Orphanet 60 ORPHA55880
MedGen 43 C0008479
SNOMED-CT via HPO 70 258211005 443520009

Summaries for Chondrosarcoma

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 55880Disease definitionChondrosarcoma is a malignant bone tumor arising from cartilaginous tissue, most frequently occuring at the ends of the femur and tibia, the proximal end of the humerus and the pelvis; and presenting with a palpable mass and progressive pain. Chondrosarcoma is usually slow growing at low histological grades and can be well managed by intralesional curettage or en-block wide resection.Visit the Orphanet disease page for more resources.

MalaCards based summary : Chondrosarcoma, also known as cartilaginous cancer, is related to chondrosarcoma, extraskeletal myxoid and extraosseous chondrosarcoma. An important gene associated with Chondrosarcoma is EXT1 (Exostosin Glycosyltransferase 1), and among its related pathways/superpathways are Endochondral Ossification and Immune response_Oncostatin M signaling via JAK-Stat in human cells. The drugs Ifosfamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are abnormality of the skeletal system and chondrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in cells derived from transformed cells that produce cartilage.

UniProtKB/Swiss-Prot : 76 Chondrosarcoma: A malignant neoplasm derived from cartilage cells. Chondrosarcomas range from slow-growing non-metastasizing lesions to highly aggressive metastasizing sarcomas.

Wikipedia : 77 Chondrosarcoma is a cancer composed of cells derived from transformed cells that produce cartilage. ... more...

Description from OMIM: 215300

Related Diseases for Chondrosarcoma

Diseases in the Chondrosarcoma family:

Localized Chondrosarcoma

Diseases related to Chondrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 chondrosarcoma, extraskeletal myxoid 34.2 EWSR1 NR4A3 TAF15 TFG
2 extraosseous chondrosarcoma 34.1 EWSR1 TAF15 TFG
3 myxoid chondrosarcoma 34.0 EWSR1 MTAP NR4A3 TAF15
4 bone chondrosarcoma 34.0 MMP1 MMP13
5 mesenchymal chondrosarcoma 34.0 NCOA2 SOX9
6 intracranial chondrosarcoma 33.8 IDH1 IDH2
7 clear cell chondrosarcoma 33.8 EXT2 PTHLH
8 periosteal chondrosarcoma 33.3 EXT1 IDH1 IDH2 NCOA2 PTHLH
9 hereditary multiple osteochondromas 32.6 EXT1 EXT2
10 multiple enchondromatosis, maffucci type 32.4 EXT1 EXT2 IDH1 IDH2
11 enchondroma 31.5 IDH1 IDH2
12 osteochondroma 30.9 EXT1 EXT2 PTHLH
13 hereditary multiple exostoses 30.6 EXT1 EXT2
14 chondroblastic osteosarcoma 30.6 IDH1 IDH2
15 enchondromatosis, multiple, ollier type 30.3 EXT1 EXT2 IDH1 IDH2 PTHLH
16 glioma susceptibility 1 30.0 IDH1 IDH2
17 bone inflammation disease 29.8 MMP1 MMP13 SOX9
18 adult mesenchymal chondrosarcoma 12.3
19 adult myxoid chondrosarcoma 12.3
20 extraskeletal mesenchymal chondrosarcoma 12.3
21 localized chondrosarcoma 12.2
22 juxtacortical chondrosarcoma 12.2
23 pediatric mesenchymal chondrosarcoma 12.0
24 pediatric myxoid chondrosarcoma 12.0
25 adult extraosseous chondrosarcoma 12.0
26 chondroid chordoma 11.4
27 bone cancer 11.3
28 exostoses, multiple, type i 11.0
29 exostoses, multiple, type ii 11.0
30 cartilage cancer 11.0
31 chordoma 10.6
32 sarcoma 10.5
33 dysplasia epiphysealis hemimelica 10.5 EXT1 EXT2
34 interval angle-closure glaucoma 10.4 IDH1 IDH2
35 adult oligodendroglioma 10.4 IDH1 IDH2
36 synovial chondromatosis 10.4
37 cytogenetically normal acute myeloid leukemia 10.4 IDH1 IDH2
38 intraductal papilloma 10.3 IDH1 IDH2
39 pediatric fibrosarcoma 10.3 EWSR1 TFG
40 pilocytic astrocytoma of cerebellum 10.3 IDH1 IDH2
41 spindle cell hemangioma 10.3 IDH1 IDH2
42 chondroma 10.3
43 nervous system cancer 10.3 EWSR1 IDH1 IDH2
44 adult astrocytic tumour 10.3 IDH1 IDH2 MMP1
45 fibroma 10.3
46 juxtacortical chondroma 10.2 EWSR1 EXT1 PTHLH
47 fibrillary astrocytoma 10.2 IDH1 IDH2
48 nodular malignant melanoma 10.2 EXT2 MTAP
49 giant cell tumor 10.2
50 degos 'en cocarde' erythrokeratoderma 10.2

Graphical network of the top 20 diseases related to Chondrosarcoma:



Diseases related to Chondrosarcoma

Symptoms & Phenotypes for Chondrosarcoma

Human phenotypes related to Chondrosarcoma:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 33 HP:0000924
2 chondrosarcoma 33 HP:0006765

Symptoms via clinical synopsis from OMIM:

58
Skel:
chondrosarcoma

Clinical features from OMIM:

215300

Drugs & Therapeutics for Chondrosarcoma

Drugs for Chondrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
2
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Early Phase 1 6055-19-2, 50-18-0 2907
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7
Histamine Approved, Investigational Phase 3 51-45-6 774
8
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
9
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11
Isophosphamide mustard Phase 3,Phase 2 0
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Early Phase 1
14 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
15 Alkylating Agents Phase 3,Phase 2,Early Phase 1
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
17 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2,Not Applicable
18 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable
19 Cola Phase 3,Phase 1,Early Phase 1
20 Central Nervous System Depressants Phase 3
21 Analgesics, Opioid Phase 3
22 Anesthetics Phase 3
23 Anesthetics, Intravenous Phase 3
24 Narcotics Phase 3
25 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
26 Adjuvants, Anesthesia Phase 3
27 Anesthetics, General Phase 3
28 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
29 Neurotransmitter Agents Phase 3,Phase 1
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Anti-Allergic Agents Phase 3
32 Serotonin Agents Phase 3
33 Serotonin Antagonists Phase 3
34 Histamine H1 Antagonists Phase 3
35 Dermatologic Agents Phase 3
36 Antipruritics Phase 3
37 Histamine Antagonists Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
40
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
41
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
42
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
43
leucovorin Approved Phase 2 58-05-9 6006 143
44
Gemcitabine Approved Phase 2,Phase 1,Not Applicable 95058-81-4 60750
45
Docetaxel Approved, Investigational Phase 2,Phase 1,Not Applicable 114977-28-5 148124
46
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
47
Loperamide Approved Phase 2 53179-11-6 3955
48
Allopurinol Approved Phase 2 315-30-0 2094
49
Mecasermin Approved, Investigational Phase 2 68562-41-4
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
6 Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base Recruiting NCT01182753 Phase 3
7 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
8 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
10 Proton Radiation for Chordomas and Chondrosarcomas Unknown status NCT01449149 Phase 1, Phase 2
11 Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma Unknown status NCT02066285 Phase 2 Pazopanib
12 Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Unknown status NCT02496741 Phase 1, Phase 2 Metformin and chloroquine combination
13 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
14 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
15 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
16 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Completed NCT01330966 Phase 2 pazopanib
17 A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Completed NCT01310816 Phase 2 IPI-926;Placebo Arm
18 S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone Completed NCT00096213 Phase 2
19 S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma Completed NCT00107419 Phase 2 pemetrexed disodium
20 Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine Completed NCT00592748 Phase 1, Phase 2
21 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride
22 A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas Completed NCT00401388 Phase 2 Perifosine
23 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
24 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Completed NCT01560260 Phase 2 Linsitinib
25 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
26 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
27 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
28 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
29 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
30 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
31 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
32 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
33 Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma Completed NCT00003308 Phase 2
34 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
35 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
36 A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Completed NCT00948961 Phase 1, Phase 2
37 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
38 Alanosine in Treating Patients With Cancer Completed NCT00062283 Phase 2 L-alanosine
39 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg Completed NCT00589121 Phase 2 Chemotherapy
40 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
41 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
42 A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Recruiting NCT03684811 Phase 1, Phase 2 FT-2102;Azacitidine;Gemcitabine and Cisplatin
43 A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Recruiting NCT02389244 Phase 2 Regorafenib;Placebo
44 Proton or Photon RT for Retroperitoneal Sarcomas Recruiting NCT01659203 Phase 1, Phase 2
45 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
46 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
47 Proton Beam Therapy for Chondrosarcoma Active, not recruiting NCT00496522 Phase 2
48 Imatinib in Patients With Desmoid Tumor and Chondrosarcoma Active, not recruiting NCT00928525 Phase 2 Imatinib Mesylate
49 Vismodegib in Treating Patients With Advanced Chondrosarcomas Active, not recruiting NCT01267955 Phase 2 Vismodegib
50 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting NCT02301039 Phase 2 Pembrolizumab

Search NIH Clinical Center for Chondrosarcoma

Cochrane evidence based reviews: chondrosarcoma

Genetic Tests for Chondrosarcoma

Genetic tests related to Chondrosarcoma:

# Genetic test Affiliating Genes
1 Chondrosarcoma 30 EXT1

Anatomical Context for Chondrosarcoma

MalaCards organs/tissues related to Chondrosarcoma:

42
Bone, Lung, Breast, Kidney, Thyroid, Brain, Endothelial

Publications for Chondrosarcoma

Articles related to Chondrosarcoma:

(show top 50) (show all 3053)
# Title Authors Year
1
Costal chondrosarcoma mimicking a breast cancer: Case report and review of literature. ( 30825641 )
2019
2
Synchronous chondrosarcoma originating from two distant ribs. ( 30623926 )
2019
3
Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells. ( 30631040 )
2019
4
Chondrosarcoma in Norway 1990-2013; an epidemiological and prognostic observational study of a complete national cohort. ( 30632866 )
2019
5
The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. ( 30644538 )
2019
6
Advanced chondrosarcoma of the pelvis: A rare case of urinary obstruction. ( 30655642 )
2019
7
MicroRNA-525 enhances chondrosarcoma malignancy by targeting F-spondin 1. ( 30655830 )
2019
8
Chondrosarcoma arising within synovial chondromatosis of the lumbar spine. ( 30719535 )
2019
9
Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1. ( 30737713 )
2019
10
Chondrosarcoma of the Hand Bones: A Report of 6 Cases and Review of the Literature. ( 30760143 )
2019
11
Does Resection of the Primary Tumor Improve Survival in Patients With Metastatic Chondrosarcoma? ( 30762691 )
2019
12
Are Limb-sparing Surgical Resections Comparable to Amputation for Patients With Pelvic Chondrosarcoma? A Case-control, Propensity Score-matched Analysis of the National Cancer Database. ( 30762693 )
2019
13
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. ( 30766792 )
2019
14
Systemic manifestations of extraskeletal myxoid chondrosarcoma associated with a novel t(2;22)(q34;q12) EWS translocation in a child and a review of the literature. ( 30776935 )
2019
15
Amphiregulin Promotes Vascular Endothelial Growth Factor-C Expression and Lymphangiogenesis through STAT3 Activation in Human Chondrosarcoma Cells. ( 30790501 )
2019
16
Resection and primary reconstruction of a massive chest wall chondrosarcoma. ( 30800326 )
2019
17
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target. ( 30808351 )
2019
18
Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision. ( 30813783 )
2019
19
Chondrosarcoma Arising in the Mastoid Involving the Intratemporal Facial Nerve. ( 30816921 )
2019
20
SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo. ( 30824188 )
2019
21
Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. ( 30827010 )
2019
22
Incarcerated hernia after internal hemipelvectomy for G2 chondrosarcoma: a preventable complication? ( 30828966 )
2019
23
Chondrosarcoma in a paediatric population: a study of 247 cases. ( 30838081 )
2019
24
Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones. ( 30845364 )
2019
25
Mesenchymal chondrosarcoma of maxilla in paediatric patient. ( 30852518 )
2019
26
Tumor thrombosis in right inferior pulmonary vein due to chondrosarcoma metastasis and systemic embolism. ( 30871821 )
2019
27
Skull Base Chondrosarcoma Caused by Ollier Disease: A Case Report and Literature Review. ( 30872199 )
2019
28
Bystander effectors of chondrosarcoma cells irradiated at different LET impair proliferation of chondrocytes. ( 30903603 )
2019
29
Recurrent high-grade chondrosarcoma abutting the right ventricular outflow tract. ( 30909712 )
2019
30
Robot-assisted radical nephrectomy for primary renal mesenchymal chondrosarcoma: case report and literature review. ( 30909775 )
2019
31
Proximal humerus chondrosarcoma.Long-term clinical and oncological outcomes. ( 30914237 )
2019
32
Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. ( 30082492 )
2019
33
Laryngeal Chondrosarcoma: A rare cause of critical upper airway obstruction. ( 29869857 )
2018
34
Secondary Chondrosarcoma Presenting with Symptoms Similar to Thoracic Outlet Syndrome. ( 29721343 )
2018
35
The role of surgical margins in chondrosarcoma. ( 29929901 )
2018
36
Sellar chondrosarcoma presenting with amenorrhea: A case report. ( 29979394 )
2018
37
Periosteal mesenchymal chondrosarcoma of the tibia. ( 29397433 )
2018
38
Dedifferentiated Chondrosarcoma Demonstrating Osteosarcomatous Differentiation. ( 29902785 )
2018
39
Tracheal chondrosarcoma and surgical management. ( 29860896 )
2018
40
Molecular and Clinicopathologic Heterogeneity of Intracranial Tumors Mimicking Extraskeletal Myxoid Chondrosarcoma. ( 29924341 )
2018
41
Mesenchymal chondrosarcoma of the orbit: Imaging features of CT and MRI. ( 29975155 )
2018
42
Chondrosarcoma third metacarpal: Diagnosis and management options. ( 29893351 )
2018
43
Primary extraskeletal mesenchymal chondrosarcoma arising from the iliac vein. ( 29332118 )
2018
44
Mesenchymal Chondrosarcoma of the Lacrimal Gland. ( 29342030 )
2018
45
Extraskeletal Myxoid Chondrosarcoma: A Comparative Study of Imaging and Pathology. ( 29977924 )
2018
46
Mosaic-pattern dedifferentiation in liposarcoma and chondrosarcoma: imaging features of an uncommon form of dedifferentiation. ( 29362843 )
2018
47
Falcine Myxoid Chondrosarcoma: A Rare Aggressive Case. ( 29492125 )
2018
48
Metastasis from Intracranial Mesenchymal Chondrosarcoma: Report of a Rare Case. ( 29972855 )
2018
49
How to Diagnose Enchondroma, Bone Infarct, and Chondrosarcoma. ( 29724496 )
2018
50
Extended endoscopic endonasal surgery for clival chordoma and chondrosarcoma: Our experience in 14 cases. ( 29691145 )
2018

Variations for Chondrosarcoma

UniProtKB/Swiss-Prot genetic disease variations for Chondrosarcoma:

76
# Symbol AA change Variation ID SNP ID
1 EXT1 p.Asn316Ser VAR_012820

ClinVar genetic disease variations for Chondrosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EXT1 NM_000127.2(EXT1): c.528_535delCAAAGTGC (p.Lys177Glufs) deletion Pathogenic rs587776540 GRCh37 Chromosome 8, 119122751: 119122758
2 EXT1 NM_000127.2(EXT1): c.528_535delCAAAGTGC (p.Lys177Glufs) deletion Pathogenic rs587776540 GRCh38 Chromosome 8, 118110512: 118110519

Cosmic variations for Chondrosarcoma:

9 (show all 12)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6940728 PALB2 bone,pelvis,chondrosarcoma,dedifferentiated c.2177C>T p.P726L 16:23629977-23629977 0
2 COSM28747 IDH1 bone,tibia,chondrosarcoma,NS c.394C>T p.R132C 2:208248389-208248389 0
3 COSM28748 IDH1 bone,humerus,chondrosarcoma,conventional c.394C>A p.R132S 2:208248389-208248389 0
4 COSM28750 IDH1 bone,femur,chondrosarcoma,conventional c.395G>T p.R132L 2:208248388-208248388 0
5 COSM28749 IDH1 bone,femur,chondrosarcoma,conventional c.394C>G p.R132G 2:208248389-208248389 0
6 COSM28746 IDH1 bone,femur,chondrosarcoma,conventional c.395G>A p.R132H 2:208248388-208248388 0
7 COSM480 HRAS bone,femur,chondrosarcoma,conventional c.34G>A p.G12S 11:534289-534289 0
8 COSM485 HRAS bone,femur,chondrosarcoma,conventional c.35G>C p.G12A 11:534288-534288 0
9 COSM1732355 H3F3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 0
10 COSM3908208 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 0
11 COSM6942013 CENPA bone,pelvis,chondrosarcoma,dedifferentiated c.199T>C p.F67L 2:26792229-26792229 0
12 COSM3908209 soft tissue,bone,sarcoma,NS c.355C>T p.R119* 9:77815650-77815650 0

Copy number variations for Chondrosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 110025 17 31160600 31198351 Translate TAF15 Chondrosarcoma

Expression for Chondrosarcoma

Search GEO for disease gene expression data for Chondrosarcoma.

Pathways for Chondrosarcoma

Pathways related to Chondrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.61 MMP13 PTHLH SOX9
2 10.43 MMP1 SERPINA3
3
Show member pathways
10.07 IDH1 IDH2

GO Terms for Chondrosarcoma

Biological processes related to Chondrosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ossification GO:0001503 9.61 EXT1 EXT2 SOX9
2 cartilage development GO:0051216 9.58 CNMD MMP13 SOX9
3 2-oxoglutarate metabolic process GO:0006103 9.49 IDH1 IDH2
4 negative regulation of chondrocyte differentiation GO:0032331 9.48 PTHLH SOX9
5 heparan sulfate proteoglycan biosynthetic process GO:0015012 9.46 EXT1 EXT2
6 skeletal system development GO:0001501 9.46 CNMD EXT1 PTHLH SOX9
7 NADP metabolic process GO:0006739 9.37 IDH1 IDH2
8 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process GO:0015014 9.32 EXT1 EXT2
9 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
10 cellular polysaccharide biosynthetic process GO:0033692 8.96 EXT1 EXT2
11 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Chondrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 acetylglucosaminyltransferase activity GO:0008375 9.37 EXT1 EXT2
2 heparan sulfate N-acetylglucosaminyltransferase activity GO:0042328 9.32 EXT1 EXT2
3 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity GO:0050508 9.26 EXT1 EXT2
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
6 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity GO:0050509 8.62 EXT1 EXT2

Sources for Chondrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....